UPDATE 1-Biogen wins U.S. approval of long acting multiple sclerosis drug
August 15, 2014 at 18:49 PM EDT
NEW YORK, AUG 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.
